ROBERT F GAGEL to Acromegaly
This is a "connection" page, showing publications ROBERT F GAGEL has written about Acromegaly.
Connection Strength
0.959
-
Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly. Horm Metab Res. 2011 Jan; 43(1):55-61.
Score: 0.386
-
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol. 2008 Nov; 159(5):517-23.
Score: 0.330
-
Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab. 1995 Sep; 80(9):2768-75.
Score: 0.134
-
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005 Oct; 90(10):5684-91.
Score: 0.067
-
Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab. 1998 Sep; 83(9):3034-40.
Score: 0.041